These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38857047)

  • 1. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer.
    Morgan KM; Riviere P; Nelson TJ; Guram K; Deshler LN; Sabater Minarim D; Duran EA; Banegas MP; Rose BS
    JAMA Netw Open; 2024 Jun; 7(6):e2415911. PubMed ID: 38857047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
    Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
    Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.
    Ma TM; Romero T; Nickols NG; Rettig MB; Garraway IP; Roach M; Michalski JM; Pisansky TM; Lee WR; Jones CU; Rosenthal SA; Wang C; Hartman H; Nguyen PL; Feng FY; Boutros PC; Saigal C; Chamie K; Jackson WC; Morgan TM; Mehra R; Salami SS; Vince R; Schaeffer EM; Mahal BA; Dess RT; Steinberg ML; Elashoff D; Sandler HM; Spratt DE; Kishan AU
    JAMA Netw Open; 2021 Dec; 4(12):e2139769. PubMed ID: 34964855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System.
    Yamoah K; Lee KM; Awasthi S; Alba PR; Perez C; Anglin-Foote TR; Robison B; Gao A; DuVall SL; Katsoulakis E; Wong YN; Markt SC; Rose BS; Burri R; Wang C; Aboiralor O; Fink AK; Nickols NG; Lynch JA; Garraway IP
    JAMA Netw Open; 2022 Jan; 5(1):e2144027. PubMed ID: 35040965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
    Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
    J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.
    Dess RT; Hartman HE; Mahal BA; Soni PD; Jackson WC; Cooperberg MR; Amling CL; Aronson WJ; Kane CJ; Terris MK; Zumsteg ZS; Butler S; Osborne JR; Morgan TM; Mehra R; Salami SS; Kishan AU; Wang C; Schaeffer EM; Roach M; Pisansky TM; Shipley WU; Freedland SJ; Sandler HM; Halabi S; Feng FY; Dignam JJ; Nguyen PL; Schipper MJ; Spratt DE
    JAMA Oncol; 2019 Jul; 5(7):975-983. PubMed ID: 31120534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study.
    Pumpalova YS; Ramakrishnan A; May M; Pentz A; Minkowitz S; Doherty S; Singh E; Chen WC; Rebbeck TR; Neugut AI; Joffe M
    Cancer Med; 2024 Jan; 13(1):e6739. PubMed ID: 38158645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of timing of salvage hormonal therapy on survival after brachytherapy for prostate cancer.
    Sagalovich D; Leapman M; Sfakianos J; Hall S; Stock R; Stone N
    Brachytherapy; 2016; 15(6):730-735. PubMed ID: 27743956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.
    Hearn JWD; Xie W; Nakabayashi M; Almassi N; Reichard CA; Pomerantz M; Kantoff PW; Sharifi N
    JAMA Oncol; 2018 Apr; 4(4):558-562. PubMed ID: 29049492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison by Race of Conservative Management for Low-Risk and Intermediate-Risk Prostate Cancers in Veterans From 2004 to 2018.
    Parikh RB; Robinson KW; Chhatre S; Medvedeva E; Cashy JP; Veera S; Bauml JM; Fojo T; Navathe AS; Malkowicz SB; Mamtani R; Jayadevappa R
    JAMA Netw Open; 2020 Sep; 3(9):e2018318. PubMed ID: 32986109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.
    Nguyen QN; Levy LB; Lee AK; Choi SS; Frank SJ; Pugh TJ; McGuire S; Hoffman K; Kuban DA
    Cancer; 2013 Sep; 119(18):3265-71. PubMed ID: 23798338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
    Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT.
    Ayoub Z; Khader J; Bulbul M; Khauli RB; Andraos TY; Shamseddine A; Mukherji D; Geara FB
    BMC Urol; 2022 Dec; 22(1):204. PubMed ID: 36503556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.